Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 1,622 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Disorder Clear all

Conditions: Age-Related Macular Degeneration
Interventions: 0.5 mg of DE-122, 1.0 mg of DE-122, 2.0 mg of DE-122, 4.0 mg of DE-122; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 5
States / cities: Mountain View, California • Walnut Creek, California • Jackson, Michigan + 2 more

Conditions: Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Interventions: Ixo-vec; Genetic
Lead sponsor: Adverum Biotechnologies, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 12
States / cities: Phoenix, Arizona • Bakersfield, California • Fullerton, California + 8 more

Conditions: Age Related Macular Degeneration
Interventions: ranibizumab (Lucentis(R)); Drug
Lead sponsor: Lawrence S. Morse, MD; Other
Eligibility: 50 Years and older
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Ganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 5
States / cities: San Diego, California • San Francisco, California • New York, New York

Conditions: Age Related Macular Degeneration
Interventions: Intravitreal Aflibercept injection; Drug
Lead sponsor: Retina Research Institute, LLC; Other
Eligibility: 50 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 3
States / cities: St Louis, Missouri • McAllen, Texas

Conditions: Diabetic Retinopathy
Interventions: AKST4290, Placebo; Drug
Lead sponsor: Alkahest, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 17
States / cities: Phoenix, Arizona • Glendale, California • Huntington Beach, California + 13 more

Conditions: Age Related Macular Degeneration (ARMD), AMD - Age-Related Macular Degeneration
Interventions: ABF-101, Placebo; Drug
Lead sponsor: Aptabio Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Geographic Atrophy, Age-Related Macular Degeneration, AMD
Interventions: OT-551 antioxidant eye drop; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 60 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Maculopathy, Age-Related, Choroidal Neovascularization
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 50 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 4
States / cities: Beverly Hills, California • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Stargardt Disease, Stargardt Disease 1, Cone Rod Dystrophy, Juvenile Macular Degeneration
Interventions: Prescreening Assessments; Diagnostic Test
Lead sponsor: Ascidian Therapeutics, Inc; Industry
Eligibility: 5 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 9
States / cities: San Francisco, California • Gainesville, Florida • Baltimore, Maryland + 5 more

Conditions: Diabetic Retinopathy
Interventions: Placebo, RG7774; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 37
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 33 more

Conditions: Healthy
Interventions: Not listed
Lead sponsor: Penn State University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Age-related Macular Degeneration, Diabetic Macular Edema, Injection Site, Injection Site Infection, Pain, Postoperative
Interventions: Proparacaine, Conjunctival culture; Drug · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Macular Degeneration
Interventions: Lutein; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Zidovudine, Acyclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1992
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Retinitis Pigmentosa
Interventions: Sub-Retinal Administration of OCU400-301; Genetic
Lead sponsor: Ocugen; Industry
Eligibility: 3 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 12
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 9 more

Conditions: Retinitis Pigmentosa
Interventions: N-Acetyl Cysteine (NAC); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Proliferative Diabetic Retinopathy (PDR)
Interventions: Vitrectomy, Endolaser, Faricimab, Panretinal Photocoagulation (PRP); Procedure · Device · Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 34
States / cities: Huntington Beach, California • Loma Linda, California • San Francisco, California + 30 more

Conditions: Macula Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane, Central Serous Retinopathy With Pit of Optic Disc, Commotio Retinae, Vitritis
Interventions: Episcleral Celecoxib; Drug
Lead sponsor: Targeted Therapy Technologies, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Radiation Retinopathy, Choroidal Melanoma
Interventions: ranibizumab; Drug
Lead sponsor: The New York Eye Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Leber Congenital Amaurosis, LCA, LCA1
Interventions: ATSN-101, ATSN-101 Diluent Solution, Prednisone, Triamcinalone Acetonide, 1% Prednisolone, Trimethoprim/polymyxin B; Drug
Lead sponsor: Atsena Therapeutics Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 2
States / cities: Portland, Oregon • Philadelphia, Pennsylvania

Conditions: Macular Degeneration
Interventions: 0.5 mg ranibizumab; Drug
Lead sponsor: Charles C Wykoff, PhD, MD; Other
Eligibility: 50 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 4
States / cities: West Columbia, South Carolina • Houston, Texas • Katy, Texas + 1 more

Conditions: Diabetes Mellitus, Macular Edema
Interventions: Vitamin E; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Gyrate Atrophy
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1978 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration

Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration

Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)

A Phase I Pharmacokinetic and Tolerance Study of 28-Day Regimens of Oral Ganciclovir

Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results

A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)

A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses

OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration

Age-related Macular Degeneration: Detection of Onset of New Choroidal Neovascularization (AMD DOC Study)

Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)

A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy

Measurement of the Eye's Blood Vessels Using the Dynamic Vessel Analyzer (DVA)

Topical Proparacaine Eye Drops to Improve the Experience of Patients Undergoing Intravitreal Injections

Lutein for Age-Related Macular Degeneration

Suppression of Cytomegalovirus Retinitis Utilizing High Dose Intravenous Acyclovir and Oral Zidovudine in Patients With AIDS

A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa

The FIGHT-RP1 Study

Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR

Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma

Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D

Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab

Laser and Medical Treatment of Diabetic Macular Edema

Gyrate Atrophy of the Choroid and Retina